Ultragenyx is trading 4.25% down today at $33.14 as the stock continues to slide amid broader biotech volatility and a lack of new company-specific catalysts.
- The move extends a downward trend from $34.61 on July 9 and $34.67 on July 8.
- Sentiment remains pressured by a Q1 2026 earnings miss and earlier trial disappointments that resulted in lowered analyst price targets.